Lowers the risk of cardiovascular mortality and heartfailure hospitalizations. ANDA 205541, held by Hetero Labs Ltd Iii. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 205541 (Metoprolol Succinate), held by Hetero Labs Ltd Iii, was first approved by FDA on Nov 6, 2020, with 2 approved supplements and 0 published complete response letters.
Metoprolol succinate extended-release tablets, are a beta-adrenergic blocker indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 6, 2020 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Aug 25, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 25, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 6, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters